BACKGROUND

The MP1000 system is a newly developed surgical robot in China. This study, based on our single-center experience, evaluates its feasibility, safety, and effectiveness in upper urological repair surgeries.

METHODS

This prospective, single-center, single-arm clinical study was conducted from June 2023 to December 2023. One surgeon performed 20 upper urinary tract repair operations using the MP1000 system. Prospective demographic data and perioperative outcomes were collected, and postoperative complications and success rates were analyzed. The ergonomics were evaluated using national aeronautics and space administration task load index (NASA-TLX).

RESULTS

All cases were successfully completed without the need to switch to standard laparoscopic or open surgery. The average docking time was 4.1 [interquartile range (IQR), 3-5] min, the average control time was 145.1 (IQR, 102-195) min, and the average operation time was 189.1 (IQR, 145-248) min. The average estimated blood loss (EBL) was 58.5 (IQR, 20-100) mL. The mean length of stay was 6.95 (IQR, 4-8) days. All patients had no postoperative lumbago symptoms and no Clavien-Dindo grade III or higher-grade complications. The estimated glomerular filtration rate (eGFR) was 99.29 (IQR, 95.39-126.14) mL/min/1.73 m on the first day after surgery, 101.13 (IQR, 89.73-124.7) mL/min/1.73 m on the third day after surgery, and 78.38 (IQR, 57.12-91.84) mL/min/1.73 m on the third months after surgery. The short-term success rate was 100%. The overall score of NASA-TLX is 6.70±4.81.

CONCLUSIONS

The MP1000 system is safe and effective for a variety of upper urinary tract repair procedures.